Rosiglitazone Has No Clinically Significant Effect on Nifedipine Pharmacokinetics

To examine the effects of repeat oral dosing of rosiglitazone on the pharmacokinetics of nifedipine, a prototype CYP3A4 substrate, a randomized, open‐label, crossover study was performed with two treatment phases separated by a washout period of at least 14 days. Twenty‐eight healthy male volunteers...

Ausführliche Beschreibung